Robert Mentz, MD
Cardiovascular Disease · Durham, NCNPI 1669670790
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $337,829 of the $489,107 with a category attached, or 69.1%. It is spread thinly across 31 manufacturers, the largest accounting for just 16.8%. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 412 payments — averaging $1187.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$82K
- Boehringer Ingelheim$68K
- Pharmacosmos Therapeutics Inc.$39K
- Lilly USA, LLC$39K
- AstraZeneca$39K
- Eli Lilly$31K
- plus $192K from 25 others
Across 36 payments — averaging $153,221 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$1.9M
- Amgen$1.4M
- Novartis$1.2M
- Merck$637K
- AstraZeneca$337K
- Medtronic$27K
- plus $2K from 1 others
What the payments were for
- Consulting fees$337,82969%
- Speaking & faculty fees$50,27010%
- Grants$5,0751%
- Travel & lodging$83,82417%
- Food & beverage$12,1092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 97 | $82,335 |
| Boehringer Ingelheim | 42 | $67,630 |
| Pharmacosmos Therapeutics Inc. | 12 | $39,247 |
| Lilly USA, LLC | 17 | $38,638 |
| AstraZeneca | 24 | $38,623 |
| Eli Lilly | 11 | $30,800 |
| Novo Nordisk | 11 | $29,182 |
| Novartis | 37 | $26,639 |
| Amgen | 23 | $24,406 |
| Novo Nordisk AS | 6 | $23,792 |
| Medtronic | 15 | $9,851 |
| Cvrx, Inc. | 24 | $9,400 |
| American Regent | 2 | $8,476 |
| Gilead | 2 | $8,375 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $7,000 |
| Vifor (international) Ltd. | 1 | $6,338 |
| Bayer | 10 | $6,267 |
| Roche Diagnostics Corporation | 7 | $6,153 |
| Abbott | 41 | $4,859 |
| ZOLL Respicardia, Inc. | 3 | $4,800 |
| Boehringer Ingelheim International GmbH | 4 | $3,499 |
| Roche Diagnostics International Ltd | 5 | $3,240 |
| Daiichi Sankyo Inc. | 2 | $2,067 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $2,000 |
| Vifor Pharma, Inc. | 1 | $1,800 |
| Astrazeneca UK Limited | 1 | $1,500 |
| Sanofi US Services Inc. | 1 | $920 |
| Pfizer | 1 | $630 |
| Edwards Lifesciences | 4 | $363 |
| Endotronix, Inc. | 2 | $216 |
| Abiomed | 1 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$71,540
- Monoferric$39,174
- VERQUVO$21,646
- BYETTA$12,286
- INJECTAFER$10,465
- Barostim Neo System$8,649
- ENTRESTO$7,645
- FARXIGA$6,106
- CD cobas Reagents$6,045
- MOUNJARO$5,200
- remede System$4,800
- Kerendia$4,383
- Corlanor$3,896
- HeartMate 3 Left Ventricular Assist Device$2,003
- LifeVest$2,000
- HeartMate 3 Left Ventricular Dev$1,504
- MK-1242$1,298
- SOTAGLIFLOZIN$920
- LEQVIO$243
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$166
How this compares
$489,107 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 165 | $156,451 |
| JardianceEmpagliflozin | 167 | $152,181 |
| EliquisApixaban | 72 | $69,650 |
| OzempicSemaglutide | 25 | $22,001 |
| FarxigaDapagliflozin Propanediol | 28 | $21,431 |
| RybelsusSemaglutide | 12 | $10,929 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 11 | $2,157 |
| Metoprolol Succinate | 130 | $1,823 |
| Eplerenone | 27 | $1,134 |
| Torsemide | 51 | $964 |
| Spironolactone | 138 | $964 |
| Atorvastatin Calcium | 53 | $717 |
| Carvedilol | 60 | $506 |
| Amiodarone Hcl | 14 | $429 |
| Rosuvastatin Calcium | 32 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $26,639 | $156,451165 claims |
| Boehringer IngelheimJardiance | $67,630 | $152,181167 claims |
| PfizerEliquis | $630 | $69,65072 claims |
| Novo NordiskOzempic, Rybelsus | $29,182 | $32,93037 claims |
| AstraZenecaFarxiga | $38,623 | $21,43128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Ankeet BhattDurham$258K
- Christopher GrangerDurham$257K
- Gary FelkerDurham$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.